Literature DB >> 24760489

Breakthrough cancer pain.

Andrew N Davies1.   

Abstract

Breakthrough pain is a distinct pain state that is common in patients with cancer pain and which is associated with significant morbidity in this group of patients. The aim of this article is to highlight important journal articles relating to breakthrough pain that have been published within the last year, including a systematic review of the epidemiology of breakthrough pain, the largest-ever study of the clinical features of breakthrough pain, and a network meta-analysis of the treatment of breakthrough pain.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24760489     DOI： 10.1007/s11916-014-0420-9

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN： 1534-3081


  30 in total

1.  Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients.

Authors:  J T Farrar; J Cleary; R Rauck; M Busch; E Nordbrock
Journal:  J Natl Cancer Inst       Date:  1998-04-15       Impact factor: 13.506

2.  Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR).

Authors:  P H Coluzzi; L Schwartzberg; J D Conroy; S Charapata; M Gay; M A Busch; J Chavez; J Ashley; D Lebo; M McCracken; R K Portenoy
Journal:  Pain       Date:  2001-03       Impact factor: 6.961

3.  Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study.

Authors:  Marie Fallon; Carlo Reale; Andrew Davies; A Eberhard Lux; Kirushna Kumar; Andrzej Stachowiak; Rafael Galvez
Journal:  J Support Oncol       Date:  2011 Nov-Dec

4.  Breakthrough pain: definition, prevalence and characteristics.

Authors:  Russell K Portenoy; Neil A Hagen
Journal:  Pain       Date:  1990-06       Impact factor: 6.961

5.  Breakthrough cancer pain: an observational study of 1000 European oncology patients.

Authors:  Andrew Davies; Alison Buchanan; Giovambattista Zeppetella; Josep Porta-Sales; Rudolf Likar; Wolfgang Weismayr; Ondrej Slama; Tarja Korhonen; Marilene Filbet; Philippe Poulain; Kyriaki Mystakidou; Alexandros Ardavanis; Tony O'Brien; Pauline Wilkinson; Augusto Caraceni; Furio Zucco; Wouter Zuurmond; Steen Andersen; Anette Damkier; Tove Vejlgaard; Friedemann Nauck; Lukas Radbruch; Karl-Fredrik Sjolund; Mariann Stenberg
Journal:  J Pain Symptom Manage       Date:  2013-03-22       Impact factor: 3.612

6.  Patient-controlled analgesia for cancer pain: a long-term study of inpatient and outpatient use.

Authors:  M L Citron; J M Kalra; V L Seltzer; S Chen; M Hoffman; M B Walczak
Journal:  Cancer Invest       Date:  1992       Impact factor: 2.176

7.  Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain.

Authors:  Richard L Rauck; Marvin Tark; Eva Reyes; Teresa G Hayes; Anthony J Bartkowiak; David Hassman; Srinivas Nalamachu; Rob Derrick; Julian Howell
Journal:  Curr Med Res Opin       Date:  2009-12       Impact factor: 2.580

Review 8.  A network meta-analysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodes.

Authors:  Giovambattista Zeppetella; Andrew Davies; Indra Eijgelshoven; Jeroen P Jansen
Journal:  J Pain Symptom Manage       Date:  2013-08-24       Impact factor: 3.612

9.  Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain.

Authors:  Neal E Slatkin; Fang Xie; John Messina; Thalia J Segal
Journal:  J Support Oncol       Date:  2007 Jul-Aug

10.  A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial.

Authors:  S Mercadante; L Radbruch; A Davies; P Poulain; T Sitte; P Perkins; T Colberg; M A Camba
Journal:  Curr Med Res Opin       Date:  2009-11       Impact factor: 2.580
View more
  7 in total

1.  Pharmacologic management of adult breakthrough cancer pain.

Authors:  Bruce Doulton
Journal:  Can Fam Physician       Date:  2014-12       Impact factor: 3.275

2.  Canadian recommendations for the management of breakthrough cancer pain.

Authors:  P Daeninck; B Gagnon; R Gallagher; J D Henderson; Y Shir; C Zimmermann; B Lapointe
Journal:  Curr Oncol       Date:  2016-04-13       Impact factor: 3.677

3.  Response to letter to the editor: "safety profile of intravenous patient-controlled analgesia for breakthrough pain in cancer patients: a case series study".

Authors:  A M Sousa; G M N Guimaraes; H A Ashmawi
Journal:  Support Care Cancer       Date:  2014-08-09       Impact factor: 3.603

4.  Response to Oral Immediate-Release Opioids for Breakthrough Pain in Patients with Advanced Cancer with Adequately Controlled Background Pain.

Authors:  Ahsan Azhar; Yu Jung Kim; Ali Haider; David Hui; Vishidha R Balankari; Margeaux Chiou Epner; Minjeong Park; Diane D Liu; Janet Williams; Susan E Frisbee-Hume; Julio A Allo; Eduardo Bruera
Journal:  Oncologist       Date:  2018-09-25

5.  [Dose-finding for treatment with a transdermal fentanyl patch : Titration with oral transmucosal fentanyl citrate and morphine sulfate].

Authors:  M Mücke; R Conrad; M Marinova; H Cuhls; F Elsner; R Rolke; L Radbruch
Journal:  Schmerz       Date:  2016-12       Impact factor: 1.107

6.  A fixed inhaled nitrous oxide/oxygen mixture as an analgesic for adult cancer patients with breakthrough pain: study protocol for a randomized controlled trial.

Authors:  Qiang Liu; Yu Wang; Xiang-Jiang Luo; Ning-Ju Wang; Ping Chen; Xin Jin; Guo-Xia Mu; Xiao-Min Chai; Yue-Juan Zhang; Yu-Xiang Li; Jian-Qiang Yu
Journal:  Trials       Date:  2017-01-11       Impact factor: 2.279

7.  Light-Induced Activation of a Specific Type-5 Metabotropic Glutamate Receptor Antagonist in the Ventrobasal Thalamus Causes Analgesia in a Mouse Model of Breakthrough Cancer Pain.

Authors:  Serena Notartomaso; Nico Antenucci; Francesca Liberatore; Giada Mascio; Stefano Vito Boccadamo Pompili; Joan Font; Mariarosaria Scioli; Livio Luongo; Antonietta Arcella; Roberto Gradini; Amadeu Llebaria; Ferdinando Nicoletti
Journal:  Int J Mol Sci       Date:  2022-07-20       Impact factor: 6.208
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.